NAD(P)H: Quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2349-2354

  Zhu, Cheng Lin ^a   Huang, Qiang ^a   Liu, Chen Hai ^a   Lin, Xian Sheng ^a   Xie, Fang ^a   Shao, Feng ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Digestive tract cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

EID: 84880264262     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2349     Document Type: Article

References (39)

1. Asombang AW, Kelly P (2012). Gastric cancer in Africa: what do we know about incidence and risk factors? Trans R Soc Trop Med Hyg, 106, 69-74.
2. Benedix F, Kube R, Meyer F, et al (2010). Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum, 53, 57-64.
3. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87.
4. Chen B, Zhou Y, Yang P, Wu XT (2010). Glutathione S-transferase M1 gene polymorphism and gastric cancer risk: an updated analysis. Arch Med Res, 41, 558-66.
5. Chen J, Lin Y, Zhang R, Huang ZJ, Pan XG (2012). Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res, 43, 58-66.
6. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
7. Compare D, Rocco A, Nardone G (2010). Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci, 14, 302-8.
8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
9. Enzinger PC, Mayer RJ (2003). Esophageal cancer. N Engl J Med, 349, 2241-52.
10. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
11. Hamajima N, Matsuo K, Iwata H, et al (2002). NAD(P)H: quinone oxidoreductase 1(NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
12. Harth V, Donat S, Ko Y, et al (2000). NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol, 73, 528-31.
13. Hlavata I, Vrana D, Smerhovsky Z, et al (2010). Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1,GSTM1,GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep, 24, 1347-53.
14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
15. Kanavos P (2006). The rising burden of cancer in the developing world. Ann Oncol, 17, 15-23.
16. Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-54.
17. Li Y, Zhang JH, Guo W, et al (2004). Polymorphism of NAD(P) H dehydrogenase (quinone)1 (NQO1) C609T and risk of esophageal neoplasm. Zhonghua Liu Xing Bing Xue Za Zhi, 25, 731.
18. Malik MA, Zargar SA, Mittal B (2011). Role of NQO1 609C>T and NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley. DNA Cell Bio, 30, 297-303.
19. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
20. Marjani HA, Biramijamal F, Rakhshani N, Hossein-Nezhad A, Malekzadeh R (2010). Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A case-control study from Iran. Genet Mol Res, 9, 239-49.
21. Mitrou PN, Watson MA, Loktionov AS, et al (2007). Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from UKFSS Study. Carcinogenesis, 28, 875-82.
22. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002). NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70.
23. Nisa H, Kono S, Yin G, et al (2010). Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer study. BMC Cancer, 10, 274.
24. Northwood EL, Elliott F, Forman D, et al (2010). Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics, 20, 315-26.
25. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
26. Racette AL, Miller RT (2011). Esophageal carcinoma: matching patients with treatment methods. JAAPA, 24, 28, 30-1.
27. Sachse C, Smith G, Wilkie MJ, et al (2002). A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis, 23, 1839-49.
28. Sarbla M, Brrzer M, Siegel D, et al (2003). Association between NAD(P)H: Quinone oxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer, 107, 381-6.
29. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
30. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306.
31. Tijhuis MJ, Visker MH, Aarts JM, et al (2008). NQO1 and NFE212 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer, 122, 1842-8.
32. Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75.
33. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP (2006). Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol, 163, 300-9.
34. van der Logt EM, Bergevoet SM, Roelofs HM, et al (2006). Role of epoxide hydrolase, NAD(P)H: quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res, 593, 39-49.
35. vov Rahden BH, Stein HJ, Langer R, et al (2005). C609T Polymorphism of the NAD(P) H: Quinone oxidoreductase 1 gene does not significantly affect susceptibility for esophageal adenocarcinoma. Int J Cancer, 113, 506-8.
36. Wang Z, Hu J, Zhong J (2012). Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C>T polymorphism with esophageal cancer risk. DNA Cell Biol, 31, 560-7.
37. Zhang J, Schulz WA, Li Y, et al (2003). Association of NAD(P)H: quinone oxidoreductase1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesi, 24, 905-9.
38. Zhang JH, Li Y, Wang R, et al (2003). The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 20, 544-6.
39. Zhou JY, Shi R, Yu HL, Zheng WL, Ma WL (2011). Association of NQO1 Pro187Ser polymorphism with the risks for colorectal cancer and colorectal adenoma: a meta-analysis. Int J Colorectal Dis, 27, 1123-4